CancerNetwork Members: Login | Register
Become a fan on  Facebook  Add us on  Google Plus Follow us on  Twitter Join us on LinkedIn Sign up for our Newsletters Subscribe to our RSS Feed

 

CancerNetwork SearchMedica Medline Drugs

Powered by SearchMedica

 
PUBLICATIONS
NEWS
PODCASTS
TOPICS
BLOGS
NURSES
PATIENTS
JOBS
CONFERENCES
CME
SUPPLEMENTS
 

Home » Practice Management

 

FDDNP-PET Shows Brain Injury in Former NFL Players

By Diagnostic Imaging Staff | January 23, 2013

PET imaging with a chemical marker called FDDNP, originally developed to look for brain plaques associated with Alzheimer’s disease, has identified abnormal tau proteins among former professional football players, say researchers in a study in the February 2013 issue of the American Journal of Geriatric Psychiatry.

“Early detection of tau proteins may help us to understand what is happening sooner in the brains of these injured athletes,” lead author Dr. Gary Small said in a release. Small is UCLA’s Parlow-Solomon Professor on Aging and a professor at the Semel Institute for Neuroscience and Human Behavior at UCLA. “Our findings may also guide us in developing strategies and interventions to protect those with early symptoms, rather than to try to repair damage once it becomes extensive.”

(MORE: MRI, PET Aids in Predicting Progression of Alzheimer’s)

Five retired National Football League players, ages 45 to 73 who played professionally for 10 to 16 years, participated in the small study. The subjects had histories of cognitive or mood symptoms and diagnoses of mild cognitive impairment, dementia, depression and normal aging.

The subjects received intravenous injections of FDDNP and then underwent positron emission tomography brain scans. Their scans were compared to men of comparable age, education, body mass index, and family history of dementia.

Results showed that the football players had higher levels of FDDNP in the amygdala and subcortical regions of the brain, which was even higher among those with the most concussions, compared with the normal scans. “The FDDNP binding patterns in the players’ scans were consistent with the tau deposit patterns that have been observed at autopsy in CTE [chronic traumatic encephalopathy] cases,” said study author Dr. Jorge R. Barrio, a professor of molecular and medical pharmacology at the David Geffen School of Medicine at UCLA.

Barrio pointed out that elevated FDDNP has been associated in studies with cognitive symptoms in normal aging, mild cognitive impairment, and dementia. Currently, FDDNP is the only imaging marker that can measure tau in living humans.

The players were also evaluated for depression and cognitive ability, and the results were compared with the normal group. The players showed more depression, as well as cognitive loss. Three players had mild cognitive impairment, one had dementia, and another had normal cognitive function.

The authors acknowledge that this is a small study, but Small pointed out that a recent study of more than 3,400 retired professional football players showed evidence of a higher-than-average risk of death from Alzheimer’s disease. More research is needed to better understand the issue, they said.

PET plus FDDNP shows brain injury in retired NFL playersCaption: The left image shows a normal brain scan and middle and right images show scans of pro football players from the study. The green and red colors demonstrate the higher level of tau protein found in the brain. Note the higher levels (more red and green) in the players’ scans. Scans of the players in the study reflect differing levels of tau protein and follow a pattern of progression similar to the tau deposits that have been observed at autopsy in CTE cases. (Credit: UCLA)

 

 

Join the Conversation

Want to join the conversation? If you're a healthcare professional, we'd like to hear your comments. Just sign in or register today to become part of our growing, online community.

Related Content

Alzheimer’s Differing Effects on Male, Female Brains

Imaging Shows Active Lifestyle Slows Alzheimer’s

PET Imaging with Amyvid for Alzheimer's

Case Study: PET Imaging with Amyvid for Alzheimer’s

New Alzheimer’s Imaging Test in Use at Mount Sinai

PET, MRI, Cerebrospinal Analysis Best for Alzheimer’s Test

FDDNP-PET Shows Brain Injury in Former NFL Players

MRI, PET Aids in Predicting Progression of Alzheimer’s






 
TOPIC INDEX

Cancer Types

 
  • Breast
  • Breast (HER2+)
  • Breast (Triple-Negative)
  • CML
  • Colorectal
  • Gastrointestinal
  • GIST
  • Genitourinary
  • Gynecologic
  • Head & Neck
  • Hematology
  • Kidney (Renal Cell)
  • Leukemia
  • Lung
  • Lymphoma
  • Melanoma
  • Multiple Myeloma
  • Ovarian
  • Prostate
  • Sarcoma

Supportive Care

More Topics

  • Bone Metastases
  • End-of-Life Care
  • Palliative Care
  • Ethics in Oncology
  • Practice Management
  • Practice & Policy


All Topics 


 
MOST POPULAR
  • Most Popular
  • Most Emailed
  • Most Recent
  • Colorectal Lesions
  • “This Is My Last Day on Earth”
  • Dermatologic Adverse Events Associated With Targeted Therapies
  • Skin Lesions
  • Slide Show: Squamous Cell Carcinoma of the Head and Neck
  • “This Is My Last Day on Earth”
  • Dermatologic Adverse Events Associated With Targeted Therapies
  • Recurrent Epithelial Ovarian Cancer: An Update on Treatment
  • Colorectal Lesions
  • ONS: Understanding Spirituality and How It Can Be Used to Help Patients
  • New AUA Guidelines for Prostate Cancer Screening
  • 50 Shades of Pink—And Why It Helps to Know the Difference
  • Genomics Studies Identify Testicular Cancer Risk Variants
  • Lower Back Pain in an Elderly Man With a History of Localized Prostate Cancer
  • FDA Approves Erlotinib (Tarceva) as First-Line Lung Cancer Therapy for Certain Patients
Click here to subscribe to our newsletter
 
COMMENTS
  • Most Commented
  • Most Recent
  • “This Is My Last Day on Earth”
  • Financial Toxicity, Part II: How Can We Help With the Burden of Treatment-Related Costs?
  • Patient Quality of Life Endpoints in Oncology Trials, Part II
  • Who's Coding Whom?
  • “How Do I Say This Nicely? Your Oncologist Wasn't Following Guidelines”
  • Preventing Exposure to Hazardous Drugs
  • Cancer Metabolism as a Therapeutic Target
  • Study: Cholesterol Drugs Reduced Risk of Prostate Cancer Death
  • “This Is My Last Day on Earth”
  • ONS: Safe Handling of Chemotherapy
Click here to subscribe to our newsletter


 
SearchMedica Search Result

Find peer-reviewed literature and websites for practicing medical professionals

CME on Practice Management
Evidence on Practice Management
Guidelines on Practice Management
Patient Education on Practice Management
Clinical Trials on Practice Management
Practical Articles on Practice Management
Research and Reviews on Practice Management
All "Practice Management" results

CancerNetwork on Facebook

CancerNetwork | ConsultantLive | Diagnostic Imaging | Musculoskeletal Network | OBGYN.net | PediatricsConsultantLive |
Physicians Practice | Psychiatric Times | SearchMedica | Medical Resources

© 1996 - 2013 UBM Medica LLC, a UBM company
Privacy Statement - Terms of Service - Advertising Information - Editorial Policy Statement - UBM Medica Network Privacy Policy